ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,483.94
      0.20%
      US Tech 100
      19,402.80
      0.00%
      Dow Jones
      38,805.23
      0.07%
      Brent Oil
      84.715
      0.97%
      Bitcoin
      64,431.27
      -3.09%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Catalyst Pharmaceuticals Inc (CPRX)

      7. Catalyst Pharmaceuticals Inc (CPRX) News

      CPRX

      Catalyst Pharmaceuticals (CPRX)

      Catalyst Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CPRX
      DateTimeSourceHeadlineSymbolCompany
      06/11/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      06/07/202411:17AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      06/05/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      06/05/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      06/04/202410:41AMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      06/03/202412:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/31/20244:50PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/31/20244:47PMEdgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/31/20244:46PMEdgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/31/20244:43PMEdgar (US Regulatory)Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/30/20244:43PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/30/20241:41PMGlobeNewswire Inc.Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/28/20248:03AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/21/20245:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/08/20244:54PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/08/20244:16PMGlobeNewswire Inc.Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/08/20244:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      05/01/20248:00AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      04/22/20248:00AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      03/28/20248:03AMGlobeNewswire Inc.Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness DayNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      03/27/20248:03AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy SymposiumNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      03/13/20247:55AMGlobeNewswire Inc.Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)NASDAQ:CPRXCatalyst Pharmaceuticals Inc
      03/05/20248:03AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/28/20246:03PMGlobeNewswire Inc.Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/27/20248:03AMGlobeNewswire Inc.Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREENASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/21/20249:00AMGlobeNewswire Inc.Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/16/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/16/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/16/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
      02/16/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CPRXCatalyst Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:CPRX